Potentially adverse interactions between haloperidol and valerian

Food and Chemical Toxicology

Volumn 46, Issue 7, 2008, Pages 2369-2375

  Dalla Corte, C L ^a   Fachinetto, R ^a   Colle, D ^a   Pereira, R P ^a   Avila D S ^a   Villarinho, J G ^a   Wagner, C ^a   Pereira, M E ^a   Nogueira, C W ^a   Soares, F A A ^a   Rocha, J B T ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Haloperidol; Herb drug interaction; Oxidative stress; Valeriana officinalis; ALA D

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CATALASE; DICHLOROFLUORESCEIN; GLUTATHIONE; HALOPERIDOL; PORPHOBILINOGEN SYNTHASE; SUPEROXIDE DISMUTASE; VALERIAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REACTIVATION; HERB DRUG INTERACTION; KIDNEY; KIDNEY FUNCTION; LIPID PEROXIDATION; LIVER; LIVER FUNCTION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DEPLETION; RAT; VALERIANA OFFICINALIS;

RATTUS; VALERIANA; VALERIANA OFFICINALIS;

EID: 84983724933     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.03.019     Document Type: Article

References (59)

1. Ablordeppey S.Y., and Borne R.F. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidolnext term-treated rats. Pharmacol. Biochem. Behav. 46 (1993) 739-744
2. Aebi H. Catalase. In: Bergmeyer H.V. (Ed). Methods of Enzymatic Analysis (1974), VEB Chemie, Weinheim 673-677
3. Ali S.F., LeBel C.P., and Bondy S.C. Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology 13 (1992) 637-648
4. Al-Majed A.A., Al-Yahya A.A., Al-Bekairi A.M., Al-Shabanah O.A., and Qureshi S. Studies on the cytological and biochemical effects of valerian in somatic and germ cells of Swiss albino mice. Food Chem. Toxicol. 44 (2006) 1830-1837
5. Andreasen O.A., and Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?. Prog. Neurobiol. 61 (2000) 525-541
6. Ang-Lee M.K., Moss J., and Yuan C.S. Herbal medicines and perioperative care. JAMA 286 (2001) 208-216
7. Ang-Lee M.K. Most commonly used herbal medicines in the USA. In: Yuan C.S., and Bieber E.J. (Eds). Textbook of Complementary and Alternative Medicine (2003), Parthenon, New York 7-32
8. Assemi M. Herbs affecting the central nervous system: gingko, kava, St. John's wort, and valerian. Clin. Obstet. Gynecol. 48 (2001) 824-835
9. Avent K.M., DeVoss J.J., and Gillam E.M. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites. Chem. Res. Toxicol. 19 (2006) 914-920
10. Bailey D.G., and Dresser G.K. Natural products and adverse drug interactions. CMAJ 170 (2004) 1531-1532
11. Bechara E.J.H., Medeiros M.H.G., Monteiro H.P., Hermes-Lima M., Pereira B., Demasi M., Costa C.A., Adballa D.S.P., Onuki J., Wendel C.M.A., and Masci P.D. A free radical hypothesis of lead poisoning and in Born porphyrias associated with 5-aminolevulinic overload. Quim. Nova 16 (1993) 385-392
12. Bechara E.J. Oxidative stress in acute intermittent porphyria and lead poisoning may be triggered by 5-aminolevulinic acid. Braz. J. Med. Biol. Res. 29 (1996) 841-851
13. Bloomquist J., King E., Wright A., Mytilineou C., Kimura K., Castagnoli K., and Castagnoli Jr N. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther. 270 (1994) 822-830
14. Brazier N.C., and Levine M.A. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am. J. Ther. 10 (2003) 163-169
15. Burger M.E., Fachineto R., Alves A., Callegari L., and Rocha J.B. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res. 1031 (2005) 202-210
16. Cavadas C., Araujo I., Cotrim M.D., Amaral T., Cunha A.P., Macedo T., and Ribeiro C.F. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung 45 (1995) 753-755
17. Creese I., Burt D.R., and Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of anti-schizophrenic drugs. Science 192 (1976) 481-483
18. Emanuelli T., Pagel F.W., Alves L.B., Regner A., and Souza D.O. Inhibition of adenylate cyclase activity by 5-aminolevulinic acid in rat and human brain. Neurochem. Int. 38 (2001) 213-218
19. Fachinetto R., Burger M.E., Wagner C., Wondracek D.C., Brito V.B., Nogueira C.W., Ferreira J., and Rocha J.B. High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats. Pharmacol. Biochem. Behav. 81 (2005) 585-592
20. Fachinetto R., Villarinho J., Wagner C., Pereira R.P., Ávila D.S., Burger M.E., Calixto J.B., Rocha J.B.T., and Ferreira J. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Prog. Neuropsychopharmacol. Biol. Psychiat. 31 (2007) 1478-1486
21. Fang J., Zuo D., and Yu P.H. Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology (Berl.) 121 (1995) 373-378
22. Fang J., Mckay G., Song J., Remillrd A., LI X., and Midha K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes. Drug Metab. Dispos. 12 (2001) 1638-1643
23. Folmer V., Soares J.C., and Rocha J.B.T. Oxidative stress in mice is dependent on the free glucose content of the diet. Int. J. Biochem. Cell Biol. 34 (2002) 1279-1285
24. Folmer V., Soares J.C., Gabriel D., and Rocha J.B.T. A high fat diet inhibits delta-aminolevulinate dehydratase and increases lipid peroxidation in mice (Mus musculus). J. Nutr. 133 (2003) 2165-2170
25. Forsman A., Folsch G., Larsson M., and Ohman R. The metabolism of haloperidol in man. Curr. Ther. Res. Clin. Exp. 21 (1977) 606-617
26. Fugh-Berman A., and Ernst E. Herb-drug interactions: review and assessment of report reliability. Br. J. Clin. Pharmacol. 52 (2001) 587-595
27. Gaertner I., Altendorf K., Batra A., and Gaertner H.J. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7263 treatment courses. J. Clin. Psychopharmacol. 21 (2001) 215-222
28. Gerlach J., and Casey D. Tardive dyskinesia. Acta Psychiat. Scand. 77 (1988) 369-378
29. Glazer W.M., Morgenstern H., Shooler N., Berkman C.S., and Moore D.C. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br. J. Psychiat. 157 (1990) 585-592
30. Gold J.L., Laxer D.A., Dergal J.M., Lanctot K.L., and Rochon P.A. Herbal-drug therapy interaction: a focus on dementia. Curr. Opin. Clin. Nutr. Metab. Care 4 (2001) 29-34
31. Gonçalves T.L., Erthal F., Corte C.L.D., Muller L.G., Piovezan C.M., Nogueira C.W., and Rocha J.B.T. Involvement of oxidative stress in the pre-malignant and malignant states of cervical cancer in women. Clin. Biochem. 38 (2005) 1071-1075
32. Gonzalez F.J. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res. 569 (2005) 101-110
33. Hadley S., and Petry J.J. Valerian. Am. Fam. Physician 67 (2003) 1755-1758
34. Hellum B.H., Hu Z., and Nilsen O.G. The Induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin. Pharmacol. Toxicol. 100 (2006) 23-30
35. Hissin P.J., and Hilf R. A fluorimetric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem. 74 (1976) 214-226
36. Houghton P.J. The scientific basis for the reputed activity of valerian. J. Pharm. Pharmacol. 51 (1999) 505-512
37. + found in rat brain following IP administration of HP. Life Sci. 57 (1995) 2439-2446
38. Kalgutkar A.S., Taylor T.J., Venkatakrishnan K., and Isin E.M. Assesment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antpsychotic agent haloperidol to its potencially neurotoxin pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab. Dispos. 31 (2003) 243-249
39. Keochanthala-Bounthanh C., Haag-Berrurier M., Beck J.P., and Anton R. Effects of thiol compounds versus the cytotoxicity of valepotriates on cultured hepatoma cells. Planta Med. 56 (1990) 190-192
40. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
41. Malva J.O., Santos S., and Macedo T. Neuroprotective properties of Valeriana officinalis extracts. Neurotox. Res. 6 (2004) 131-140
42. Mennini T., Bernasconi P., Bombardelli E., and Morazzoni P. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 64 (1993) 291-300
43. Misra H.P., and Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and simple assay for superoxide dismutase. J. Biol. Chem. 247 (1972) 3170-3175
44. Ohkawa H., Ohishi H., and Yagi K. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 (1979) 351-358
45. Perottoni J., Meotti F.C., Folmer V., Pivetta L., Nogueira C.W., Zeni G., and Rocha J.B.T. Ebselen and diphenyl diselenide do not change the inhibitory effect of lead acetate on delta aminolevulinate dehydratase. Environ. Toxicol. Pharmacol. 19 (2005) 239-248
46. Reitman S., and Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol. 28 (1957) 56-63
47. Richman A., and Witkowski J.P. 4th Annual Herbal Products Sales Survey. Whole Foods 21 (1998) 19-26
48. Richman A., and Witkowski J.P. 5th Annual Herbal Products Sales Survey. Whole Foods 22 (1999) 49-56
49. Rollema H., Skolnik M., D'Engelbronner J., Igarashi K., Usuki E., and Castagnoli Jr. N. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268 (1994) 380-387
50. Santos F.W., Zeni G., Rocha J.B.T., Nascimento P.C., Marques M.S., and Nogueira C.W. Efficacy of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and diphenyl diselenide on cadmium induced testicular damage in mice. Food Chem. Toxicol. 43 (2005) 1723-1730
51. Sassa S. Delta-aminolevulinic acid dehydratase assay. Enzyme 28 (1982) 133-145
52. See R.E., and Ellison G. Intermittent and continuous haloperidol regimens produce different types of oral dyskinesias in rats. Psychopharmacology (Berl.) 100 (1990) 404-412
53. Soares J.C., Folmer V., and Rocha J.B.T. Influence of dietary selenium supplementation and exercise on thiol-containing enzymes in mice. Nutrition 19 (2003) 627-632
54. Subramanyam B., Woolf T., and Castagnoli Jr N. Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem. Res. Toxicol. 4 (1991) 123-128
55. Usuki E., Pearce R., Parkinson A., and Castagnol Jr N. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem. Res. Toxicol. 9 (1996) 800-806
56. Von der Hude W., Scheutwinkel-Reich M., Braun R., and Dittmar W. In vitro mutagenicity of valepotriates. Arch. Toxicol. 56 (1985) 267-271
57. Yao J.K., Reddy R., McElhinny L.G., and van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiat. Res. 32 (1998) 385-391
58. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., and Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res. 788 (1998) 215-222
59. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., and Watkins P.B. The human CYP3A subfamily: practical considerations. Drug Metab. Rev. 32 (2000) 339-361